These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 20622169

  • 1. Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats.
    Cummings BP, Stanhope KL, Graham JL, Baskin DG, Griffen SC, Nilsson C, Sams A, Knudsen LB, Raun K, Havel PJ.
    Diabetes; 2010 Oct; 59(10):2653-61. PubMed ID: 20622169
    [Abstract] [Full Text] [Related]

  • 2. Growth hormone treatment does not augment the anti-diabetic effects of liraglutide in UCD-T2DM rats.
    Swarbrick MM, Cox CL, Graham JL, Knudsen LB, Stanhope K, Raun K, Havel PJ.
    Endocrinol Diabetes Metab; 2023 Jan; 6(1):e392. PubMed ID: 36480511
    [Abstract] [Full Text] [Related]

  • 3. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.
    Harder H, Nielsen L, Tu DT, Astrup A.
    Diabetes Care; 2004 Aug; 27(8):1915-21. PubMed ID: 15277417
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes.
    Moffett RC, Patterson S, Irwin N, Flatt PR.
    Diabetes Metab Res Rev; 2015 Mar; 31(3):248-55. PubMed ID: 25256010
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Liraglutide prevents diabetes progression in prediabetic OLETF rats.
    Guo N, Sun J, Chen H, Zhang H, Zhang Z, Cai D.
    Endocr J; 2013 Mar; 60(1):15-28. PubMed ID: 22986487
    [Abstract] [Full Text] [Related]

  • 8. Subcutaneous administration of leptin normalizes fasting plasma glucose in obese type 2 diabetic UCD-T2DM rats.
    Cummings BP, Bettaieb A, Graham JL, Stanhope KL, Dill R, Morton GJ, Haj FG, Havel PJ.
    Proc Natl Acad Sci U S A; 2011 Aug 30; 108(35):14670-5. PubMed ID: 21873226
    [Abstract] [Full Text] [Related]

  • 9. Deterioration of plasticity and metabolic homeostasis in the brain of the UCD-T2DM rat model of naturally occurring type-2 diabetes.
    Agrawal R, Zhuang Y, Cummings BP, Stanhope KL, Graham JL, Havel PJ, Gomez-Pinilla F.
    Biochim Biophys Acta; 2014 Sep 30; 1842(9):1313-23. PubMed ID: 24840661
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
    Schwasinger-Schmidt T, Robbins DC, Williams SJ, Novikova L, Stehno-Bittel L.
    Pharmacol Res; 2013 Oct 30; 76():58-66. PubMed ID: 23891763
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats.
    Larsen PJ, Wulff EM, Gotfredsen CF, Brand CL, Sturis J, Vrang N, Knudsen LB, Lykkegaard K.
    Diabetes Obes Metab; 2008 Apr 30; 10(4):301-11. PubMed ID: 18333889
    [Abstract] [Full Text] [Related]

  • 15. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, Chapman IM.
    Diabetes Res Clin Pract; 2012 Aug 30; 97(2):258-66. PubMed ID: 22446097
    [Abstract] [Full Text] [Related]

  • 16. Liraglutide: the therapeutic promise from animal models.
    Knudsen LB.
    Int J Clin Pract Suppl; 2010 Oct 30; (167):4-11. PubMed ID: 20887299
    [Abstract] [Full Text] [Related]

  • 17. [The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
    Yan L, Wang S, Chen P, Chen C, Shao Z, Xu X, Huang Q.
    Zhonghua Nei Ke Za Zhi; 2015 Apr 30; 54(4):307-12. PubMed ID: 26268058
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.
    Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I.
    Cardiovasc Diabetol; 2012 Sep 14; 11():107. PubMed ID: 22973968
    [Abstract] [Full Text] [Related]

  • 19. [Effect of liraglutide on glucagon secretion in obese type 2 diabetic patients].
    Sun XF, Wang Y, Zhao WJ, Wang L, Bao DQ, Qu GR, Yao MX, Luan J, Wang YG, Yan SL.
    Zhonghua Nei Ke Za Zhi; 2019 Jan 01; 58(1):33-38. PubMed ID: 30605948
    [Abstract] [Full Text] [Related]

  • 20. Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat.
    Cummings BP, Strader AD, Stanhope KL, Graham JL, Lee J, Raybould HE, Baskin DG, Havel PJ.
    Gastroenterology; 2010 Jun 01; 138(7):2437-46, 2446.e1. PubMed ID: 20226188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.